Onset

Typical antidepressant response emerges over 2-6 weeks. Initial 1-2 weeks: orthostatic hypotension, mild stimulation/insomnia (especially if dosed PM), occasional initial fatigue paradoxically. Therapeutic effect: gradual mood lift, reduction in anhedonia, return of motivation, often with notably energizing character (vs the more sedating phenelzine).

Sustained

Patients in remission on Parnate often describe the response as more complete than they experienced on SSRIs — restored emotional range (not blunted), restored libido (vs SSRI sexual dysfunction), restored drive. This is the basis for the "MAOI is the best antidepressant I ever took" narrative seen in TRD patient communities. The tradeoff is the dietary restriction + drug-interaction overhead, which patients describe as a real but manageable lifestyle cost once routinized.

Activation profile vs Nardil

Parnate is reported as more activating, less sedating, more weight-neutral or weight-loss-leaning than phenelzine. Many TRD patients on phenelzine who experience excess sedation/weight gain are switched to Parnate. Conversely, anxious patients who find Parnate too activating may be switched to phenelzine. Selection between the two often comes down to symptom cluster: anergic/atypical/leaden → Parnate; anxious/agitated/insomnia → phenelzine.

• Tolerance: Antidepressant effect generally maintained. Some patients develop "poop-out" at 1-3 years requiring dose increase or switch.
• Cycling: Not cycled — chronic continuous use for clinical indication. The drug doesn't lend itself to cycling because of the 2-week MAO regeneration period that surrounds any discontinuation.
• Reset / washout: 2 weeks for full enzyme regeneration before any drug or dietary change. This is non-negotiable.

Synergistic with (clinical practice)

• Mood stabilizers (lithium, lamotrigine, valproate) — used as MAOI augmentation in some TRD/bipolar protocols. Lithium augmentation of Parnate is an established practice with case-series evidence.
• Atypical antipsychotics (low-dose quetiapine, aripiprazole) — sometimes added cautiously for residual symptoms in TRD; not a primary stack.
• Thyroid (T3/Cytomel) — historical MAOI augmentation strategy.

Avoid stacking with — absolute contraindications

• All SSRIs: sertraline, fluoxetine (5-week washout), paroxetine, citalopram, escitalopram, fluvoxamine — serotonin syndrome
• All SNRIs: venlafaxine, duloxetine, desvenlafaxine, milnacipran — serotonin syndrome
• All TCAs: amitriptyline, clomipramine (worst), imipramine, nortriptyline, desipramine — serotonin syndrome / hypertensive crisis
• Other MAOIs: phenelzine, isocarboxazid, selegiline (especially Emsam patch tiers), rasagiline, safinamide, moclobemide, linezolid (antibiotic), methylene blue (procedural)
• Bupropion (Wellbutrin): hypertensive crisis + seizure risk
• Tramadol, meperidine (Demerol), methadone, fentanyl-class: serotonin syndrome / hyperpyrexia. Standard non-serotonergic opioids (morphine, oxycodone, hydromorphone) are generally OK with caution.
• Dextromethorphan (DXM): psychosis + serotonin syndrome — avoid all DXM-containing cough syrups
• MDMA, methamphetamine, cocaine, amphetamine high-dose: catastrophic — combined hypertensive crisis + serotonin syndrome
• 5-HTP, L-tryptophan high-dose: serotonin syndrome
• St. John's Wort: serotonin syndrome
• Sympathomimetics (OTC): pseudoephedrine, phenylephrine, ephedrine — hypertensive crisis. Excludes most cold/flu OTCs from the formulary.
• Stimulant ADHD medications: Adderall, Vyvanse, Dexedrine, Ritalin, Concerta — hypertensive crisis (relative — some clinicians cautiously co-prescribe at low dose in specialty TRD-ADHD overlap, but this is high-risk specialist territory)
• Buspirone: serotonin syndrome risk
• Triptans: sumatriptan, rizatriptan, zolmitriptan, etc. — serotonin syndrome
• Reserpine, guanethidine: opposing or synergistic adrenergic effects
• Local anesthetics with epinephrine/cocaine: hypertensive crisis — flag for dental work

Caution / monitor

• Anesthesia: disclose to anesthesiologist 2+ weeks pre-op; some surgical procedures require MAOI washout before general anesthesia.
• CYP enzymes: Parnate is not strongly metabolized by CYP2D6/2C19/3A4 like SSRIs are; pharmacokinetic drug interactions are less of an issue than the pharmacodynamic ones above.

The drug-interaction surface for Parnate is enormous and overlaps multiple OTC categories. A non-exhaustive list of commonly-encountered hazards:

• OTC cold/flu remedies: virtually all of them contain pseudoephedrine, phenylephrine, or DXM. Allowed: guaifenesin (mucinex), saline, plain acetaminophen/ibuprofen.
• OTC dietary supplements: 5-HTP, tryptophan, St. John's Wort, SAM-e (serotonin syndrome risk), tyrosine high-dose (theoretical adrenergic risk), yohimbine (sympathomimetic), DMAA/synephrine pre-workouts.
• Recreational drugs: MDMA, cocaine, methamphetamine, ketamine + amphetamine combos — all catastrophic. Cannabis generally considered tolerable (no serotonergic interaction at standard doses) but contributes to orthostatic hypotension.
• Prescription: TCAs, SSRIs, SNRIs, atypical antidepressants (mirtazapine relatively safer per some clinicians but still flagged), tramadol, meperidine, triptans, buspirone, dextromethorphan, sympathomimetic ADHD stimulants.
• Dietary supplements: caffeine generally OK at usual doses; high-dose pre-workouts containing yohimbine/synephrine/DMAA are NOT OK; theanine/glycine/taurine/magnesium/B-vitamins generally fine.

Parnate is a direct MAO suicide-inhibitor — pharmacokinetic CYP polymorphisms are largely irrelevant compared to the pharmacodynamic interaction surface. The genotypes that matter:

• MAOA-uVNTR (the "warrior gene") — affects baseline MAO-A activity. Low-activity MAOA carriers may experience disproportionate response (and side effects) at given dose; theoretically less Parnate is needed.
• MAOB intron 13 (rs1799836) — affects MAO-B baseline expression; may influence response.
• 5-HTTLPR (SERT promoter) — short-allele carriers historically considered higher SSRI side-effect risk; relevance to MAOI response is less clear.
• COMT Val158Met (rs4680) — Val/Val (low DA tone) may benefit more from MAOI's DA preservation effect.

These are research-tier signals, not actionable clinical decision criteria in 2026. There is no validated pharmacogenomic test that predicts Parnate response or dose.

For users in this archetype: this is Rx-and-psychiatrist-only territory. There is no sane self-directed sourcing path for Parnate — the drug interaction and dietary surface require clinical oversight.

Baseline (before starting)

• Resting BP + orthostatic BP delta (lying → standing, 1 + 3 minutes)
• HR resting
• Liver panel (ALT/AST/bilirubin)
• Sodium baseline
• ECG (QT interval — though Parnate is generally cardiac-safe, baseline is useful)
• Mood self-report scale (PHQ-9 or HAM-D)
• Comprehensive medication review including OTC + supplements

During use

• Resting + orthostatic BP weekly first month, monthly thereafter
• HR monitoring
• Liver panel every 3-6 months (LFT elevation rare but documented)
• Mood / PHQ-9 every 4-6 weeks
• Tyramine/sympathomimetic exposure log if any uncertain meal or OTC encounter

Post-discontinuation

• 2-week observation for tyramine/drug-interaction safety window
• Mood baseline reassessment for relapse risk